News Conference News AHA 2019 LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE Michael O'Riordan November 13, 2019
News Daily News Recurrent Events Common Among Young Patients With CAD Michael O'Riordan October 11, 2019
News Conference News ESC 2019 ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date Yael L. Maxwell September 03, 2019
News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019
News Conference News SCCT 2019 Time to Ease Up on Prior Authorization for PCSK9 Inhibitors? Yael L. Maxwell July 15, 2019
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Daily News Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony Michael O'Riordan March 15, 2019
News Daily News Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable Shelley Wood February 12, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019